The rational of a fixed combination of benzoyl peroxide and niacinamide in the treatment of acne vulgaris: A narrative review
| Published |
| January 18, 2024 |
| Title |
| The rational of a fixed combination of benzoyl peroxide and niacinamide in the treatment of acne vulgaris: A narrative review |
| Authors |
| Massimo Milani MD, PHD(a) and Francesca Colombo BSC(a) |
| Keywords |
| Acne; Rosacea; Benzoyl Peroxide; Niacinamide; Fixed combination |
| Downloads |
 |
Massimo Milani MD, PHD(a) and Francesca Colombo BSC(a)
(a)Cantabria Labs Difa Cooper Medical Department, Caronno Pertusella (VA), Via Milano 160; Italy
Correspondence:
Dr Massimo Milani MD, PHD: massimo.milani@difacooper.com
Dr Francesca Colombo: francesca.colombo@difacooper.com
Abstract
Acne vulgaris (AV) in a common skin disease affecting mainly adolescents but could be present also in adult subjects. AV is characterized by the presence of non-inflammatory (comedons) and inflammatory (papules, pustules, cysts, and nodules) lesions affecting sebaceous glands rich regions like the face, back, shoulder and thorax. A central pathogenetic role of AV lesions seems played by Cutibacterium acnes, especially some phylotypes (i.e. C. acne IA1) able to induce an inflammatory response at the level of sebaceous glands. Other important pathogenetic factors of AV are the adrogen-driven increase of sebum production and the process of hyperkeratinisation of the infundibulum. The first line treatment of AV is in general done using monotherapy with antibacterial agents like benzoyl peroxide (BPO) and hydrogen peroxide or topical retinoid molecules. These two classes of drugs could interfere with C. acnes growth (BPO) and with keratinocytes proliferation (retinoid). Fixed combination of BPO and retinoid molecules are commonly used in mild to moderate forms of AV. However, both BPO and retinoids could be nor well tolerated especially during the first weeks of treatment causing skin irritation erythema and and dryness. Both BPO and topical retinoids could interfere with the skin barrier function. During BPO treatment the Trans epidermal water loss (TEWL) a marker of skin barrier function, increase significantly supporting the fact that BPO alters this function. Niacinamide is a potent anti-inflammatory molecule able to preserve the skin barrier function. Niacinamide has shown to be effective in AV with inflammatory lesions. There is a strong rationale for the development of a topical product formed by fixed combination of BPO and niacinamide for the first-line treatment of mild to moderate AV but also in the treatment of papulopustular rosacea. In this narrative review we discuss the rational of the combination and the first clinical data of this product as first line AV and rosacea treatment strategy.
Introduction Acne vulgaris and Rosacea pathogenesis and the rational of treatment
Acne vulgaris (AV) is a common skin inflammatory disease affecting the pilosebaceous unit [1]. AV pathogenesis involves four main processes: increase in sebum production; follicular hyperkeratinisation with sebaceous follicles obstruction; Propionibacterium acnes (Cutibacterium acnes) proliferation; and inflammation [2]. Some strains of C. acnes (IA1) are crucial in starting the inflammatory response in the AV lesions formation [3]. Colonisation of the pilosebaceous follicle by C. acnes is considered as a main factor causing acne by inducing the inflammatory response of the skin [4]. Two other factors playing a relevant role in this chronic inflammatory skin disease are the quantitative and qualitative modification of sebum production, with a modification of its composition, and the hyper cornification process of the pilosebaceous follicle resulting from hyperproliferation and abnormal differentiation of keratinocytes [5]. Environmental factors, hormones, family history and stress are also other contributing factors that influence the severity as well the incidence and persistence of acne [6]. AV is characterized by an alteration in the skin barrier function even in absence of anti-acne aggressive treatments such as oral or topical retinoids [7]. Rosacea is a very common, chronic inflammatory disease characterized by flushing, erythema, and inflammatory lesions, affecting the face [8]. Inflammatory lesions of Rosacea (papules and pustules) are very similar to the AV inflammatory lesions even if the are characterized by some difference in the distribution in the regions of the face [9]. Also, rosacea is characterized by a relevant skin barrier function alteration [10]. Commonly, AV is treated using topical products, alone or in combination, such as benzoyl peroxide (BPO), retinoids and antibiotics [11]. These classes of drugs could interfere with C. acnes growth (BPO and antibiotics) and with keratinocytes proliferation (retinoid). Fixed combination of BPO and retinoid molecules are commonly used in mild to moderate forms of AV [12]. However, both BPO and retinoids could be not well tolerated especially during the first weeks of treatment causing skin irritation erythema and dryness with negative influences on the compliance to the treatment [13]. Clinical success of acne treatments is deeply influenced by adherence or compliance to the therapy [14]. Low skin tolerability and/or low efficacy are the main reason of the lack of compliance. Therefore, an ideal treatment for AV could be able to interfere with the pathogenetic mechanisms involved in AV lesions formation. Topical metronidazole or topical and oral antibiotics like doxycycline are used in the treatment of inflammatory Rosacea [15]. BPO is not commonly used in Rosacea due to its irritative action on the skin, even if new formulation of BPO have recently showed to be effective and well tolerated also in this skin condition [16].
